-
Administration characterised 2025 as a 12 months of transition, shifting the enterprise mannequin towards direct affected person care which now represents nearly all of whole income.
-
Efficiency was impacted by doctor turnover and reimbursement dynamics, alongside anticipated headwinds inside the Medical Tools Leasing section.
-
The corporate stabilized its doctor base by means of a brand new collaboration with Brown College Well being, which is starting to drive enhancements in therapy volumes.
-
Operational focus has shifted towards enhancing income cycle administration infrastructure to achieve higher management over billing and collections.
-
Worldwide progress stays a core pillar, with the Puebla, Mexico middle exceeding expectations and a brand new facility in Guadalajara anticipated to start operations in 2026.
-
The corporate is actively engaged in constructive discussions with lenders to restructure credit score amenities following a breach of sure monetary covenants at year-end.
-
Strategic positioning is centered on long-term well being system partnerships, exemplified by a 7-year lease extension with Orlando Well being for proton beam remedy.
-
Administration expects therapy volumes to proceed enhancing into 2026 because the stabilized doctor crew in Rhode Island ramps up operations.
-
The event pipeline features a new radiation remedy middle in Bristol slated for late 2027 and a proton beam middle in Johnston for 2028.
-
Future monetary flexibility is contingent upon reaching an settlement with lenders to resolve substantial doubt concerning the corporate’s capability to proceed as a going concern.
-
Growth technique depends on leveraging current skilled workers throughout new regional websites to handle bills throughout preliminary facility ramp-up durations.
-
Administration goals to drive margin enchancment by aligning the fee construction with the elevated scale of the direct affected person care platform.
-
The corporate reported a internet lack of $1.6 million for 2025, in comparison with a previous 12 months revenue that was skewed by a $3.8 million discount buy acquire.
-
Capital expenditures of $7.5 million for Rhode Island and worldwide expansions considerably decreased money reserves to $3.7 million at year-end.
-
Three Gamma Knife contract expirations drove a 14.8% decline in fourth-quarter income as well being techniques opted to finance their very own capital expenditures.
-
Administration acknowledged a ‘steep low cost’ in market valuation relative to a shareholders’ fairness of $3.66 per excellent share.
